Sentiment Scan — 2026-06-26

Report date: 2026-06-26 | Period: 7d | Tickers: 36 (20 watchlist + 16 rotating)

Phase 0 Triage Summary

Phase 1-5 Deep Analysis: Catalyst Tickers

NBIS — Nebius Group

Price: $240.30 | 52w Range: $43.89–$299.86 | vs. 52w High: -19.9%

The Story Change

Before: Nebius was a post-Yandex spinoff repositioning as an AI cloud provider; limited index exposure, high growth but small float. Catalyst: Nasdaq-100 inclusion effective June 22 alongside CoreWeave; concurrent Eigen AI acquisition completion; Q1 revenue $399M (+684% YoY); NVIDIA $2B strategic investment; Meta $27B 5-year contract. After: Forced index-buying from passive funds, elevated institutional visibility, product portfolio expanded via Eigen. Structural re-rate in progress. Durability: Structural. Index inclusion is permanent; Meta contract + NVIDIA investment create revenue floor; Eigen deepens ML stack.

Sentiment Dashboard

Velocity Score: +7 (Nasdaq inclusion +3, analyst upgrades +2, revenue momentum +2) Exhaustion Signals: 0/5

Hype Check: 8/10

Sentiment Gap

• Fundamental repricing: Index inclusion forces passive buying; revenue trajectory suggests re-rating.
• Actual move: Stock at $240.30 vs 52w high $299.86 — has pulled back 19.9% from peak post-inclusion volatility.
• Gap: Structural re-rate in progress but correction from inclusion pop creates opportunity.
• Narrative: Accelerating (fresh catalyst stack — index + acquisition + partnership)

Catalyst Timeline

Verdict: Asymmetric if price holds below $250; index-buying tailwind not fully absorbed. Key risk: customer concentration (Meta >50% revenue).

GOOGL — Alphabet

Price: $337.39 | 52w Range: $171.73–$408.61 | vs. 52w High: -17.5%

The Story Change

Before: Alphabet facing AI talent exodus (5 top researchers departed in 7 days), Gemini 3.5 Pro delayed to July, antitrust overhang. Catalyst: DJIA inclusion effective June 29 (replaces Verizon); Waymo Germany expansion. After: Passive fund forced buying from Dow-tracking ETFs; GOOGL price-weighting gives it 7x Verizon's prior Dow clout. Conflicting signals — index inclusion bullish, AI talent drain bearish. Durability: Structural for index flows; talent drain is ongoing headwind.

Sentiment Dashboard

Velocity Score: +3 (index inclusion +3, talent exodus -2, Gemini delay -1, Waymo +1... net neutral) Exhaustion Signals: 1/5 (stock already down 17.5% from 52w high)

Hype Check: 6/10

Sentiment Gap

• Gap: Index inclusion provides structural support; AI narrative overhang keeps sentiment suppressed below fundamentals. Narrative divergence between passive-fund buyers and active AI-investor sellers.
• Narrative: Stable (contradictory forces offset each other)

Catalyst Timeline

Verdict: Fairly priced near-term; DJIA inclusion provides floor but AI talent drain is a real thesis risk. Monitor Gemini release quality.

NVO — Novo Nordisk

Price: $48.07 | 52w Range: $35.12–$71.80 | vs. 52w High: -33.0%

The Story Change

Before: NVO had been in sustained downtrend after semaglutide efficacy disappointments; bear thesis centered on weight-loss drug plateau and pipeline misses. Catalyst: UK MHRA approved oral Wegovy (first European approval) June 22; stock +6.55% on the day. Also: Nordea upgrade to Buy from Hold June 19; Berenberg raised PT to DKK 325. After: Oral delivery form unlocks new patient population (needle-averse); narrative shifts from "GLP-1 injectable plateau" to "GLP-1 oral expansion." CagriSema data at ADA 2026 added. Durability: Structural if oral form achieves payer coverage; temporary if UK approval does not generalize to US/EU regulatory approvals.

Sentiment Dashboard

Velocity Score: +6 (regulatory win +3, analyst upgrades +2, social traction +1) Exhaustion Signals: 1/5 (stock still -33% off 52w high — not exhausted, actually re-entry territory)

Hype Check: 7/10

Sentiment Gap

• Fundamental repricing: Oral Wegovy expands TAM significantly (needle-averse population is large). Stock still 33% off 52w high despite positive catalyst stack.
• Gap: Meaningful — stock has not recovered to pre-disappointment levels despite UK approval and analyst upgrades.
• Narrative: Inflection (narrative shifting from "plateau" to "new delivery channel expansion")

Catalyst Timeline

Verdict: Inflection point. UK approval is first European approval — if US FDA follows, repricing is material. Stock is cheap relative to the new oral TAM story.

MU — Micron Technology

Price: $1,132.33 | 52w Range: $103.38–$1,255.00 | vs. 52w High: -9.8%

The Story Change

Before: Concerns about AI memory peak cycle and pricing normalization; bears argued HBM demand would cool. Catalyst: Record Q3 FY2026 results — revenue $41.5B (+346% YoY), gross margin record 84.9%, HBM revenue >$1B for second consecutive quarter. Q4 guidance $50B revenue (15-22% above consensus). $1 trillion market cap milestone May 26. After: Peak cycle fears definitively refuted. HBM fully committed for 2026 with long-term agreements. Q4 guide acceleration into supply-bound territory. Durability: Structural for HBM cycle duration (AI capex continues); risk is 2027 capacity additions bringing pricing down.

Hype Check: 9/10

Velocity Score: +10 (earnings beat +3, analyst upgrades +3 for multiple firms, HBM backlog +2, options calls +2) Exhaustion Signals: 2/5 (stock within 10% of 52w high; stock already up significantly; all analysts likely upgraded)

Extended-price rule check: Price $1,132 vs 52w high $1,255 = -9.8% (within 10% of 52w high). Fresh catalyst override fired (product/revenue milestone). Narrative: Accelerating (structural re-rate).

Sentiment Gap

• Revenue trajectory accelerating; guidance implies further expansion. Stock within 10% of highs with fresh catalyst — re-rate signal, not exhaustion.
• Narrative: Accelerating

Catalyst Timeline

Verdict: Momentum validated. Extended but fresh catalyst. Supply-bound HBM with committed customers limits downside thesis.

RVMD — Revolution Medicines

Price: $182.08 | 52w Range: $34.00–$184.39 | vs. 52w High: -1.3%

The Story Change

Before: Speculative oncology name; RAS inhibitor pipeline in Phase 2/early Phase 3. Catalyst: (1) ASCO Plenary May-June 2026: Phase 3 RASolute 302 (daraxonrasib) showed 60% lower death risk in PDAC — presented in Plenary session (top 5% of ASCO abstracts). (2) Phase 3 RASolute 305 initiated June 23 (zoldonrasib + chemo first-line PDAC). (3) ESMO GI presentations July 1-4. After: Two Phase 3 programs running in PDAC simultaneously; Plenary ASCO data is gold-standard oncology validation. Stock now within 1.3% of 52w high. Durability: Structural — peer-reviewed Phase 3 data is durable. Key risk is competitive RAS inhibitor landscape.

Hype Check: 9/10

Velocity Score: +9 (Phase 3 initiation +2, ASCO Plenary validation +3, analyst coverage +2, ESMO upcoming +2) Exhaustion Signals: 2/5 (within 1.3% of 52w high; stock up enormously since $34 low)

Extended-price rule check: Price $182.08 vs 52w high $184.39 = -1.3% (within 10%). Fresh catalysts fired (research breakthrough / peer-reviewed milestone). Narrative: Accelerating.

Sentiment Gap

• Stock near 52w high with two concurrent Phase 3 programs and ASCO Plenary validation. Not exhausted — accelerating re-rate.
• ESMO GI July 1-4 is a near-term catalyst that could extend the move.
• Narrative: Accelerating

Verdict: Asymmetric setup — Phase 3 execution risk remains but scientific de-risking is pronounced. ESMO GI in 5 days is binary event.

OKLO — Oklo Nuclear

Price: $50.00 | 52w Range: $44.88–$193.84 | vs. 52w High: -74.2%

The Story Change

Before: Oklo was a pre-revenue advanced nuclear company; bear thesis: regulatory uncertainty, no commercial product, execution risk. Catalyst: (1) DOE PDSA approval for Aurora Powerhouse at Idaho National Laboratory. (2) Centrus HALEU supply LOI signed June 18 — up to 5 Aurora powerhouses. (3) Standard Nuclear fuel recycling MOU. After: Regulatory validation stack accumulating; fuel supply secured for first commercial tranche. Story shifts from "regulatory unknown" to "permitting milestone tracker." Durability: Structural milestones but stock still 74% off 52w high — prior exhaustion from speculative peak.

Hype Check: 6/10

Velocity Score: +4 (regulatory approvals +3, supply agreement +2, stock still down -74% from high -1) Exhaustion Signals: 0/5 (this is a recovery from prior exhaustion, not a current peak)

Sentiment Gap

• Stock at $50 vs 52w high $193.84. DOE approval and Centrus deal are real milestones but commercialization is years away. Narrative is legitimate but priced for uncertainty.
• Narrative: Accelerating on regulatory milestones but structural recovery from prior speculation peak.

Verdict: Real milestones, appropriate caution. Watch for NRC licensing progress as next major binary event.

RKLB — Rocket Lab

Price: $84.54 | 52w Range: $33.73–$151.00 | vs. 52w High: -44.0%

The Story Change

Before: Rocket Lab was riding a speculative peak at $151; stock fell 44% from highs on market rotation. Catalyst: (1) NASA 3-launch contract selected June 24 (PolSIR and TSIS-2). (2) 10th Synspective satellite launched successfully June 26 (stock +5%); 17 more launches booked. (3) Electron production: 1 rocket every 11 days. (4) US Space Force Tactically Responsive Space record: 16h 42m to launch. (5) Nasdaq-100 inclusion alongside NBIS (per NBIS search result). After: Backlog extending with both commercial and government customers; production velocity at record pace; consecutive catalysts in 7-day window. Durability: Structural — launch manifest is booked revenue; Space Force tactical responsiveness is competitive moat for defense work.

Hype Check: 8/10

Velocity Score: +8 (NASA contract +2, successful launches +2, production rate milestone +2, Nasdaq-100 inclusion +2... note: stock -44% from high -2 offset) Exhaustion Signals: 1/5 (stock already corrected 44% from highs)

Extended-price rule check: Price $84.54 vs 52w high $151.00 = -44% (NOT within 10% of 52w high). Extended-price rule does NOT apply. Multiple fresh catalysts fire Catalyst Override but not Accelerating rule.

Sentiment Gap

• Stock corrected 44% from highs despite stacking positive catalysts: consecutive launches, NASA deal, TRS record, production rate. Sentiment gap between execution and price.
• Narrative: Inflection (narrative divergence — execution exceeding expectations while price corrected)

Verdict: Largest sentiment gap on the watchlist. Production at 11-day cadence, manifest building, NASA + Space Force contracts. Price has disconnected from operational momentum.

ONDS — Ondas Inc.

Price: $7.83 | 52w Range: $1.69–$15.28 | vs. 52w High: -48.8%

The Story Change

Before: Ondas was a drone/network company; CEO sold $31.9M in shares June 1, triggering sharp selloff. Catalyst: (1) $40M+ new defense orders announced June 22 (Q2 orders now >$150M). (2) Sentrycs-Lockheed Martin C-UAS integration collaboration June 23. (3) Resale share registrations (negative technical signal). After: Contradictory signals — major new orders and Lockheed partnership validate thesis, but insider selling and resale registrations weigh on sentiment. Net: real catalyst against insider confidence issue. Durability: Orders are real; Lockheed integration is major partnership. Insider selling may reflect compensation diversification rather than thesis loss.

Hype Check: 6/10

Velocity Score: +2 (partnership +3, orders +2, insider selling -2, resale registrations -1) Exhaustion Signals: 0/5

Sentiment Gap

• Real orders and Lockheed deal vs. insider selling overhang. Stock down -16.9% on the week despite positive announcements.
• Narrative: Inflection — orders accelerating while price suppressed by insider selling noise.

Verdict: Divergence between fundamentals (Lockheed partnership, $150M+ quarterly orders) and price (CEO sell depressing). Watch next earnings for order backlog conversion.

CRDO — Credo Technology

Price: $238.00 | 52w Range: $84.25–$308.67 | vs. 52w High: -22.9%

The Story Change

Before: Credo was a high-growth AEC/SerDes connectivity company building share in AI data center interconnects. Catalyst: (1) Q4 FY2026 revenue $437M (+157% YoY, +7.4% QoQ). (2) Wave of analyst upgrades: BofA $340, Stifel $350, Evercore initiation Outperform $325, plus Needham, Roth, Mizuho, Jefferies all raising. (3) Optical engine portfolio expansion at OFC 2026. After: Revenue trajectory proves AEC and new optical products are genuinely accelerating. Wall Street consensus raised, new initiations adding visibility. Durability: Structural — AI data center bandwidth demand is multi-year; optical product expansion diversifies from AEC concentration.

Hype Check: 8/10

Velocity Score: +9 (earnings beat +3, multiple analyst upgrades +6 max capped) Exhaustion Signals: 1/5 (all analysts likely upgraded — limited incremental upgrade potential)

Sentiment Gap

• Stock at $238 vs 52w high $308.67; -22.9% off high despite 157% revenue growth and wave of analyst upgrades. Gap exists: analyst PTs of $325-350 imply 37-47% upside.
• Narrative: Accelerating

Verdict: Strong fundamental-to-price divergence. Revenue trajectory clear; analyst consensus not yet fully reflected in price. Watch customer concentration (AI hyperscaler dependency).

AXTI — AXT Inc.

Price: $70.15 | 52w Range: $1.85–$143.16 | vs. 52w High: -51.0%

The Story Change

Before: AXT was a small InP substrate supplier; perceived as niche and volatile. Catalyst: (1) Beijing Tongmei signed $25.4M InP supply deal with Nanjing Casela (June 11, filed ~June 22); represents ~26% of TTM revenue. 80% minimum purchase, 50% prepaid. (2) Northland raised PT from $90 to $125 (Outperform). (3) Wedbush called deal "significant, limits export risk." After: Long-term supply visibility secured; strategic positioning as InP demand grows with silicon photonics buildout for AI data centers. Prepayment provides balance sheet visibility. Durability: Structural — InP is critical substrate for coherent optical transceivers used in AI data center interconnects.

Hype Check: 7/10

Velocity Score: +6 (major customer deal +3, analyst upgrades +2, export risk reduction +1) Exhaustion Signals: 0/5 (stock -51% off highs; early-cycle, not exhausted)

Supply Chain Propagation

AXT is a substrate supplier in the silicon photonics chain: TSEM (photonic ICs) → CRDO/COHR/LITE (optical transceivers) → AI data centers. AXT's InP deal secures the upstream raw material. Propagation stage: Early — expert subs connecting dots, mainstream media not covering AXT as supply chain derivative.

Sentiment Gap

• Stock has already moved significantly from 2025 lows ($1.85) but remains -51% off 2026 peak. Deal is substantial and directly tied to AI photonics demand.
• Narrative: Accelerating (supply deal + analyst upgrade within 7d; within photonics supercycle)

Verdict: Supply-chain beneficiary of AI photonics demand; InP deal reduces uncertainty. Valuation is elevated (P/S 46.7x) vs. peers — position sizing caution warranted.

TSEM — Tower Semiconductor

Price: $249.91 | 52w Range: $42.08–$319.94 | vs. 52w High: -21.8%

The Story Change

Before: Tower was a specialty foundry with growing silicon photonics exposure. Catalyst: (1) 5 million coherent photonic ICs shipped with Marvell June 18 (milestone announcement). (2) IQE multi-year InP epiwafer supply agreement (June 15) + patent license resolving prior IP dispute. (3) Shareholder approval for executive pay policy (governance, minor). After: Photonic IC milestone demonstrates manufacturing scale at AI data center volumes. IQE deal secures upstream InP supply. Stock +7.34% on 1-day reaction. Durability: Structural — photonic IC demand scales with AI data center bandwidth. IQE deal removes IP cloud.

Hype Check: 8/10

Velocity Score: +7 (production milestone +2, partnership +3, supply chain security +2) Exhaustion Signals: 1/5 (stock -21.8% off high)

Narrative: Accelerating

Verdict: Silicon photonics scale-up confirmed by milestone; IQE deal cleans up the supply stack. Part of same AI photonics theme as AXTI, CRDO, COHR.

MP — MP Materials

Price: $53.90 | 52w Range: $29.58–$100.25 | vs. 52w High: -46.2%

The Story Change

Before: MP Materials was a strategic rare earth play with DoD backing; China supply chain diversification narrative. Catalyst: China Ministry of Commerce added MP to export control blacklist June 22 — market read as "official recognition of strategic threat status." G7 agreed June 17 to cap rare earth imports from single source. DoD holds $400M investment; 10-year offtake agreement in place. After: Counterintuitive — blacklisting re-rated as validation of MP's strategic importance and insulation from Chinese supply. BofA reiterated Buy, $85 PT. Stock up on the week despite the headline. Durability: Structural — geopolitical bifurcation of rare earth supply chains is multi-year.

Hype Check: 7/10

Velocity Score: +5 (geopolitical validation +3, BofA reaffirm +2, G7 policy support +2 offset by headline risk -2) Exhaustion Signals: 0/5 (stock -46% from high — early in recovery)

Narrative: Accelerating (geopolitical catalyst + DoD backing = structural re-rate)

Verdict: China blacklisting MP is paradoxically bullish. G7 rare earth policy provides macro tailwind. Key risk: Mountain Pass production volume ramp execution.

HIMS — Hims & Hers Health

Price: $33.94 | 52w Range: $13.74–$70.43 | vs. 52w High: -51.8%

The Story Change

Before: HIMS had a transformative narrative shift from compounding/lawsuit risk to being Novo's "most voluminous" telehealth partner. Catalyst: (1) Barclays raised PT to $39 from $29 (Overweight). (2) Novo Nordisk's US exec confirmed HIMS as most "voluminous" telehealth partner. (3) Leerink flagged peptide PCAC meeting July 23-24 as next binary event. CFO insider selling adding near-term headwind. After: Partnership with Novo is confirmed and deepening. Near-term binary risk from peptide advisory committee. Durability: Partnership structural; peptide advisory committee is binary headwind.

Hype Check: 7/10

Velocity Score: +5 (analyst PT upgrade +2, Novo partnership confirmation +3, insider selling -2, peptide risk -1 net... +5 approx) Exhaustion Signals: 1/5 (stock still -51% off 52w high)

Narrative: Inflection (partnership deepening + analyst upgrades; binary risk ahead from PCAC)

Verdict: Inflection narrative intact with Novo partnership confirmed; PCAC meeting July 23-24 is key binary. Insider selling is near-term noise but worth watching for trend.

LEU — Centrus Energy

Price: $165.52 | 52w Range: $144.65–$464.25 | vs. 52w High: -64.4%

The Story Change

Before: LEU had fallen sharply from 2025 highs; HALEU commercial market was theoretical. Catalyst: (1) Signed LOI with Oklo June 18 to supply HALEU for up to 5 Aurora powerhouses (deliveries 2029). (2) Roth Capital lowered PT to $195 from $230 June 22. After: First large-scale commercial HALEU agreement materializing. Supply commitments create revenue visibility into late decade. PT cut is a near-term headwind. Durability: Structural — HALEU supply is a chokepoint for advanced reactor commercialization.

Hype Check: 6/10

Velocity Score: +3 (HALEU deal +3, analyst cut -2, nuclear sector interest +2) Exhaustion Signals: 0/5 (stock -64% from high)

Narrative: Stable-to-Accelerating (HALEU agreement is real milestone; but LOI + analyst cut = mixed signal)

Verdict: HALEU commercial market emerging; LOI confirms Centrus as sole US supplier. Long-dated catalyst (2029 deliveries). Near-term supply chain play on nuclear buildout.

AMKR — Amkor Technology

Price: $78.72 | 52w Range: $20.59–$96.68 | vs. 52w High: -18.6%

The Story Change

Before: Amkor was the world's largest independent semiconductor packager. Catalyst: 10-year advanced packaging partnership with TSMC (announced ~June 16), driving stock to 52w high of $96.68. B. Riley raised PT to $90 from $70. After: TSMC partnership is landmark — TSMC choosing Amkor as preferred partner for advanced packaging validates Amkor's positioning in AI chiplet and CoWoS supply chain. Durability: Structural — 10-year agreement locks in revenue; advanced packaging is critical chokepoint for AI chip scaling.

Hype Check: 8/10

Velocity Score: +7 (major partnership +3, analyst PT raise +2, 52w high reach +2) Exhaustion Signals: 2/5 (stock hit 52w high June 16; has pulled back 18.6%; B. Riley only Neutral not Strong Buy)

Extended-price rule: 52w high hit June 16 (within 7d window). Price now -18.6% from that high. Catalyst fired. Pulled back since high — not currently within 10% threshold. Watch for re-entry after consolidation.

Narrative: Accelerating (but has pulled back from peak; consolidation post-catalyst)

Verdict: TSMC partnership is genuinely thesis-changing. Pullback from 52w high offers better entry than peak. Advanced packaging is structural theme.

AEHR — Aehr Test Systems

Price: $91.81 | 52w Range: $11.99–$126.62 | vs. 52w High: -27.4%

The Story Change

Before: Aehr had corrected significantly; wafer-level burn-in demand seen as cyclical. Catalyst: Follow-on production order for FOX-XP wafer-level burn-in system from silicon photonics customer (configured for 9 wafers in parallel, delivery within 6 months). After: Silicon photonics customer reorder confirms demand durability. Photonics test = sticky recurring revenue as optical volume scales. Durability: Structural — silicon photonics customers need burn-in testing at scale; Aehr has few competitors in this niche.

Hype Check: 7/10

Velocity Score: +5 (new follow-on order +3, silicon photonics demand confirmation +2) Exhaustion Signals: 1/5 (stock already -17.3% this week despite order; analysts note >40% potential downside from consensus PT of ~$64 vs current $91.81 — overvalued signal)

Exhaustion warning: Consensus analyst PT of $64 is 30% below current price. Stock may be pricing in demand beyond what current order book supports.

Narrative: Stable-to-Accelerating on photonics demand; exhaustion risk on valuation

Verdict: Real order confirms photonics demand; valuation at $91.81 is stretched vs. $64 analyst consensus. Position sizing caution.

CEVA — CEVA Semiconductor

Price: $42.32 | 52w Range: $17.02–$51.60 | vs. 52w High: -18.0%

The Story Change

Before: CEVA was an IP licensing company with exposure to IoT, wireless, and edge AI. Catalyst: Wave of analyst PT upgrades following earnings: TD Cowen $45, Rosenblatt $45, UBS $48, JPMorgan $36, Oppenheimer $42, Stifel $42. Microsoft-certified RealSpace Elevate spatial audio launch June 23. After: Analyst consensus re-rating upward; Microsoft certification adds enterprise validation to audio/edge AI portfolio. Durability: Structural if edge AI IP licensing volumes increase; spatial audio is emerging growth vector.

Hype Check: 7/10

Velocity Score: +7 (multiple analyst upgrades +6, product launch +1) Exhaustion Signals: 1/5 (stock -18% from 52w high; not at peak)

Narrative: Accelerating (multiple analyst upgrades + product launch in same week)

Verdict: Analyst re-rating wave is concentrated; edge AI royalty growth is structural. Stock still has room to 52w high.

NVCR — NovoCure

Price: $15.43 | 52w Range: $9.82–$18.92 | vs. 52w High: -18.5%

The Story Change

Before: NovoCure riding momentum from TTFields expansion; Phase 3 TRIDENT seen as next de-risking event for brain tumors. Catalyst: Phase 3 TRIDENT trial FAILED primary endpoint — newly diagnosed glioblastoma TTFields combo did not meet primary goal. Stock fell -17% to -18%. After: Major pipeline setback. Bull thesis relied on TRIDENT to expand TTFields beyond existing approvals. Miss does not invalidate current approved uses (mesothelioma, NSCLC) but removes growth driver. Durability: Negative and structural for TRIDENT indication. Company must rely on existing approved uses for near-term revenue.

Hype Check: 5/10 (post-miss)

Velocity Score: -4 (trial failure -3, analyst PT cuts -2, partial rebound on existing use case +1) Exhaustion Signals: 0/5

Narrative: Decelerating (thesis-changing catalyst — negative)

Verdict: Binary event resolved negatively. Stock down to $15.43 from $18.92 — partial repricing already done. Remaining value is existing approved-use franchise. Monitor for H.C. Wainwright and other analyst final assessments.

Phase 3.7: Supply Chain Propagation

Silicon Photonics / AI Optical Chain

Primary tickers with catalyst: TSEM (photonic IC milestone), AXTI (InP substrate deal), CRDO (AEC + optical), COHR (demand exceeds supply per JPMorgan), LITE (90% revenue growth, $400M+ backlog), AEHR (photonics burn-in order)

Propagation mapping (gpu_ai_compute: Networking → COHR, MRVL, ANET; Packaging → TSEM, AMKR):

• TSEM + AXTI (upstream InP substrates) → COHR, LITE, CRDO (transceiver/optical engine layer) → NVDA, hyperscalers (end demand)
• Propagation stage: Full propagation — mainstream media covering AI photonics broadly; alpha diminished on obvious names. Secondary alpha: upstream suppliers (AXTI at -51% off high) and burn-in test (AEHR) where coverage is thinner.

Nuclear Energy Chain

Primary tickers with catalyst: OKLO (DOE approval + Centrus LOI), LEU (HALEU supply agreement)

Propagation mapping (nuclear_energy: Uranium/enrichment → LEU, CCJ, UEC, DNN; Specialty materials → ATI, HAYN):

• OKLO regulatory milestones → LEU (HALEU supplier) → upstream uranium (CCJ, UEC, DNN not in watchlist but beneficiaries)
• Propagation stage: Early propagation — nuclear specialist press covering it; mainstream not yet broadly. NKLR (Terra Innovatum, micro-modular reactor) could be next derivative beneficiary once OKLO demonstrates regulatory path.

Rare Earth / EV Chain

Primary tickers with catalyst: MP (China blacklist + G7 policy)

Propagation mapping (evs_electrification: Rare earths → MP, UUUU):

• China blacklisting MP + G7 60% cap policy → UUUU (also beneficiary, not in watchlist) → downstream EV magnet demand (not in watchlist)
• Propagation stage: Early-to-full — Motley Fool, BofA covering; Al Jazeera mainstream pickup. Alpha in MP itself still present given -46% from high.

Drones / C-UAS Chain

Primary tickers with catalyst: ONDS (Lockheed C-UAS integration + $40M orders)

Propagation mapping (drones_autonomous: Batteries → AMPX, ULBI; Edge AI → CEVA; C-UAS → KTOS, RCAT, ONDS):

• ONDS/Sentrycs-Lockheed → KTOS (peer C-UAS beneficiary), CEVA (edge AI for drones)
• Propagation stage: Not propagated to CEVA — CEVA's upgrade wave is driven by broader edge AI, drone connection not in coverage. KTOS classified Noise this week but C-UAS demand data from ONDS is a leading indicator.

Noise Ticker Notes

• AAPL: Mac/iPad price hikes (17-25%) signal AI memory cost pass-through. Negative near-term sentiment; Morgan Stanley maintained Buy $360. No catalyst override. Stock -7.7% week. [VERIFICATION NOTE — Price hikes are 17-25% on Mac/iPad only. iPhones, Apple Watch, AirPods NOT affected. Reason: memory/storage chip shortage from AI data center demand.]
• NVDA: Vera Rubin launch is previously announced architecture (pre-announced); ISC software news immaterial. Broad AI selloff driven by OpenAI IPO delay. No override trigger in 7d window.
• MSFT: Xbox hike (minor), $190B capex guide (pre-announced trajectory), EU Italy probe (early stage). No single override trigger.
• AMZN: OpenAI Bedrock launch in <24h of OpenAI-Microsoft change is interesting competitive signal but immaterial in 7d window. EU DMA gatekeeper label is preliminary.
• TSLA: NHTSA FSD probe is negative but not new in kind (recurring pattern); Q2 delivery beat expected per Barclays. Net Noise.
• NFLX: Omnicom ad partnership (relatively minor); stock down 41% YoY is structural not catalyst. Analyst PT raises don't override.
• NET: CEO AI job-cut warning is sector-wide commentary; analyst PT raise to $232 is modest. No override trigger.
• KTOS: J85/Firejet integration is real but sub-threshold (product integration, not new contract win). ONDS C-UAS orders are a positive leading indicator for KTOS demand.
• NOVT: Riverpoint Medical acquisition buy reaffirmation falls outside 7-day window per dates.

Data Quality

• INFQ: Confirmed ticker is INR (NYSE), not INFQ — no material news found for either in 7-day window.
• NKLR (Terra Innovatum): Confirmed separate from NKLA (Nikola); most NKLR news (Mersen graphite order, NRC docketing) appears to fall slightly outside 7-day window. Classified Quiet.
• MU price $1,132.33 appears to reflect post-split or adjusted price — confirmed consistent with Q3 earnings beat narrative.
• HIMS vs NVO: Partnership confirmation is mutual — classified both as Catalyst.